Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript

Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate Therapeutics, Inc.

Keep Reading →